Literature DB >> 1815761

Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements.

M Vecchi1, M Cattaneo, R de Franchis, P M Mannucci.   

Abstract

A large number of hemostasis measurements complications were performed in 20 patients with inflammatory bowel disease; whose changes have been associated with an increased risk of thromboembolic. Of the 20 patients, 9 (45%) had one or more changes suggestive of activation of the hemostatic system. Such changes were more frequently observed in patients with active disease. Two patients had changes in the fibrinolytic system (high plasminogen activator inhibitor-1 levels) and 2 in the natural anticoagulants (low antithrombin III activity). Nine patients had increased plasma fibrinogen levels and 6 patients had slightly increased levels of anticardiolipin antibodies. Most of the changes observed were not related to the type, location or activity of the disease. These data show that various biochemical abnormalities may be found in patients with inflammatory bowel disease, which may account for their increased risk of thrombosis, and suggest that multiple mechanisms may interact in determining such complications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815761     DOI: 10.1007/BF02591637

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  13 in total

1.  Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Dilaveraki; I G Vlachonikolis; E Vardas; G Vrentzos; E Ganotakis; I A Mouzas; A Gravanis; D Emmanouel; E A Kouroumalis
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.

Authors:  C Folwaczny; N Noehl; S P Endres; W Heldwein; K Loeschke; H Fricke
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

4.  Increased levels of homocysteine in patients with ulcerative colitis.

Authors:  Sabiye Akbulut; Emin Altiparmak; Firdevs Topal; Ersan Ozaslan; Metin Kucukazman; Ozlem Yonem
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

5.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

6.  Anti-cardiolipin antibodies in patients with inflammatory bowel disease.

Authors:  B W Aichbichler; W Petritsch; G A Reicht; H H Wenzl; A J Eherer; T A Hinterleitner; P Auer-Grumbach; G J Krejs
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

7.  Hyperhomocysteinemia in ulcerative colitis is related to folate levels.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

8.  Arterial thrombosis in ulcerative colitis. Transcatheter thrombolytic therapy.

Authors:  S J Lengle; P Nadler; G W Jordan
Journal:  West J Med       Date:  1995-06

9.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

Review 10.  Venous thromboembolism with inflammatory bowel disease.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.